The global blood transfusion diagnostics market accounted for US$ 3,813.1 Mn in 2020 with a considerable CAGR of 6.7% during the forecast period of 2021 to 2028.
Blood transfusion is the intravenous administration of blood products or blood into the circulatory system. Blood transfusion is used in a variety of medical conditions to replace lost blood components. Previously, whole blood was used for transfusion; however, modern medical methods can only use a component of blood for transfusion. Blood transfusion is one of the most common procedures performed on hospital patients. Hence, clinicians must be aware about the proper administration of blood products, as well as symptoms, signs, and transfusion reaction management. Red blood cells, platelets, plasma, albumin, and immunoglobulin preparations are all blood products that can be transfused into the human body.
Report coverage
| Market |
Blood Transfusion Diagnostics Market |
| Analysis Period |
2017 - 2028 |
| Base Year |
2020 |
| Forecast Data |
2021 - 2028 |
| Segments Covered |
By Product, By Application, By End-Use, and By Geography |
| Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled |
Abbott, BAG Healthcare GmbH, Immucor Inc., Danaher, Quotient Limited, Bio-Rad Laboratories, Ortho Clinical Diagnostics, F. Hoffmann-La Roche AG, DiaSorin S.P.A., BIOKIT (Werfen), among others. |
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
| Customization Scope |
10 hrs of free customization and expert consultation
|
The rising commonness of chronic and infectious ailments alike as cancer, kidney disorder, liver complaints, hemophilia, anemia, sickle cell condition, and thrombocytopenia, as well as the preface of technologically advanced products, are among the factors driving blood transfusion diagnostics market demand. Likewise, the growing number of cases suffering from anemia, which necessitates red blood cell transfusion for treatment, is anticipated to drive up demand for blood transfusion diagnostics. According to the World Health Organization, anemia is the most common blood disease, affecting further than 1.62 billion people worldwide, or24.8 percent of the population. Aplastic anemia can be treated with drugs and blood transfusions. Alternatively, the high cost of tests, instruments, and reagents, combined with a lack of skilled professionals to handle automated diagnostic solutions, is one of the factors limiting the growth of the blood transfusion diagnostics market during the forecast period.
Segmentation
Based on the product segment, the reagent and kits segments dominated the market in 2020. The key factors driving the kits & reagents segment are growing need for blood screening due to rise in surgeries globally, rise in chronic diseases that require blood transfusion in regular basis and high awareness about blood transmitted diseases. The segment's growth has been fueled by the product's easy availability and repeat purchases for screening of blood samples of donors and recipient.
Based on the application segment, the disease screening held the largest market share in 2020. For disease screening, blood transfusion diagnostics are widely used. The disease screening segment is attributed to an increase in the incidence of transfusion-transmitted diseases (TTIs), increased safety screening of given blood to maintain safe transfusion, and rising technical improvements.
Based on the end-user segment, the blood bank segment accounted for the largest market share in 2020 due to growing number of blood banks globally as well as moderate increase in the blood donation due to supportive government initiatives and programs for blood donations. Increased disease screening and blood group testing performed before transfusion therapy promote the blood bank segment.
Based on region, North America was the leading market for blood transfusion diagnostics in 2020. Growing number of blood transfusion procedures in the US and Canada drives the demand for blood transfusion diagnostic kits to eliminate the risk any complication during the use of such blood; also stringent policies regarding the safety and precautionary measures also drive the market.
Competitive Landscape
Companies in this market are constantly implementing rigorous strategies to enhance the development and manufacturing of blood diagnostic tests, increasing the market share over others. Some of the major participants in the blood transfusion diagnostics market are Abbott, BAG Healthcare GmbH, Immucor Inc., Danaher, Quotient Limited, Bio-Rad Laboratories, Ortho Clinical Diagnostics, F. Hoffmann-La Roche AG, DiaSorin S.P.A., BIOKIT (Werfen), among others.
- In June 2021, DiaSorin has introduced the LIAISON Murex Anti-HEV IgG & IgM assay for the detection of Hepatitis E (HEV). This is the first CLIA-approved fully automated high-throughput HEV test, and it is available in countries that accept the CE Mark for use on the LIAISON family platforms.
- In July 2019, Abbott announces FDA approval of the ALINITY S system, the most recent technology for screening and protecting the blood and plasma supply in the United States. This new solution will bring cutting-edge screening technology to blood and plasma centers in the US. In comparison to commercially available competitive systems, ALINITY S is designed to screen blood and plasma more efficiently in a smaller space.
Market Segmentation
Market By Product
- Reagents & Kits
- Instruments
- Others
Market By Application
- Blood Grouping
- Disease Screening
- Serological Disease Screening
- Molecular Disease Screening
Market By End-use
Market By Geography
- North America
- Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Blood Transfusion Diagnostics
1.1. Definition and Scope
1.1.1. Definition of Blood Transfusion Diagnostics
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Blood Transfusion Diagnostics market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Blood Transfusion Diagnostics By Product
1.2.3. Blood Transfusion Diagnostics By Application
1.2.4. Blood Transfusion Diagnostics By End-Use
1.2.5. Blood Transfusion Diagnostics by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Blood Transfusion Diagnostics Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Blood Transfusion Diagnostics Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Blood Transfusion Diagnostics Major Manufacturers in 2019
CHAPTER 5. Blood Transfusion Diagnostics By Product
5.1. Introduction
5.2. Blood Transfusion Diagnostics Revenue By Product
5.2.1. Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast, By Product, 2017-2028
5.2.2. Reagents & Kits
5.2.2.1. Reagents & Kits Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
5.2.3. Instruments
5.2.3.1. Instruments Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
5.2.4. Others
5.2.4.1. Others Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
CHAPTER 6. Blood Transfusion Diagnostics Market Revenue By Application
6.1. Introduction
6.2. Blood Transfusion Diagnostics Revenue (US$ Bn) By Application
6.2.1. Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
6.2.2. Blood Grouping
6.2.2.1. Blood Grouping Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
6.2.3. Disease Screening
6.2.3.1. Disease Screening Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
6.2.3.1.1. Serological Disease Screening
6.2.3.1.1.1. Serological Disease Screening Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
6.2.3.1.2. Molecular Disease Screening
6.2.3.1.2.1. Molecular Disease Screening Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
CHAPTER 7. Blood Transfusion Diagnostics Market By End-use
7.1. Introduction
7.2. Blood Transfusion Diagnostics Revenue (US$ Bn) By Product
7.2.1. Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
7.2.2. Hospitals
7.2.2.1. Hospitals Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
7.2.3. Blood Banks
7.2.3.1. Blood Banks Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
7.2.4. Diagnostic Laboratories
7.2.4.1. Diagnostic Laboratories Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
7.2.5. Others
7.2.5.1. Others Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
CHAPTER 8. North America Blood Transfusion Diagnostics Market By Country
8.1. North America Blood Transfusion Diagnostics Overview
8.2. U.S.
8.2.1. U.S. Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
8.2.2. U.S. Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
8.2.3. U.S. Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
8.3. Canada
8.3.1. Canada Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
8.3.2. Canada Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
8.3.3. Canada Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
8.4. North America PEST Analysis
CHAPTER 9. Europe Blood Transfusion Diagnostics Market By Country
9.1. Europe Blood Transfusion Diagnostics Overview
9.2. U.K.
9.2.1. U.K. Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
9.2.2. U.K. Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
9.2.3. U.K. Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
9.3. Germany
9.3.1. Germany Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
9.3.2. Germany Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
9.3.3. Germany Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
9.4. France
9.4.1. France Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
9.4.2. France Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
9.4.3. France Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
9.5. Spain
9.5.1. Spain Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
9.5.2. Spain Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
9.5.3. Spain Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
9.6. Rest of Europe
9.6.1. Rest of Europe Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
9.6.2. Rest of Europe Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
9.6.3. Rest of Europe Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Blood Transfusion Diagnostics Market By Country
10.1. Asia Pacific Blood Transfusion Diagnostics Overview
10.2. China
10.2.1. China Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
10.2.2. China Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
10.2.3. China Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
10.3. Japan
10.3.1. Japan Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
10.3.2. Japan Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
10.3.3. Japan Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
10.4. India
10.4.1. India Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
10.4.2. India Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
10.4.3. India Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
10.5. Australia
10.5.1. Australia Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
10.5.2. Australia Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
10.5.3. Australia Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
10.6. South Korea
10.6.1. South Korea Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
10.6.2. South Korea Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
10.6.3. South Korea Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
10.7.2. Rest of Asia-Pacific Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
10.7.3. Rest of Asia-Pacific Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Blood Transfusion Diagnostics Market By Country
11.1. Latin America Blood Transfusion Diagnostics Overview
11.2. Brazil
11.2.1. Brazil Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
11.2.2. Brazil Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
11.2.3. Brazil Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
11.3. Mexico
11.3.1. Mexico Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
11.3.2. Mexico Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
11.3.3. Mexico Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
11.4. Rest of Latin America
11.4.1. Rest of Latin America Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
11.4.2. Rest of Latin America Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
11.4.3. Rest of Latin America Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Blood Transfusion Diagnostics Market By Country
12.1. Middle East & Africa Blood Transfusion Diagnostics Overview
12.2. GCC
12.2.1. GCC Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
12.2.2. GCC Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
12.2.3. GCC Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
12.3. South Africa
12.3.1. South Africa Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
12.3.2. South Africa Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
12.3.3. South Africa Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Product, 2017-2028
12.4.2. Rest of Middle East & Africa Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By Application, 2017-2028
12.4.3. Rest of Middle East & Africa Blood Transfusion Diagnostics Revenue (US$ Bn) and Forecast By End-use, 2017-2028
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Blood Transfusion Diagnostics
13.1. Blood Transfusion Diagnostics Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Blood Transfusion Diagnostics market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. COMPANY PROFILE
14.1. Abbott Laboratories
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (US$ Bn), 2020
14.1.3.2. Abbott Laboratories 2020 Blood Transfusion Diagnostics Business Regional Distribution
14.1.4. Product/ Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. BAG Healthcare GmbH
14.3. Immucor Inc.
14.4. Danaher
14.5. Ortho Clinical Diagnostics
14.6. Bio-Rad Laboratories
14.7. F. Hoffmann-La Roche AG
14.8. Quotient Limited
14.9. DiaSorin S.P.A.
14.10. BIOKIT (Werfen)
